JP2019524821A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524821A5
JP2019524821A5 JP2019507811A JP2019507811A JP2019524821A5 JP 2019524821 A5 JP2019524821 A5 JP 2019524821A5 JP 2019507811 A JP2019507811 A JP 2019507811A JP 2019507811 A JP2019507811 A JP 2019507811A JP 2019524821 A5 JP2019524821 A5 JP 2019524821A5
Authority
JP
Japan
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019507811A
Other languages
English (en)
Japanese (ja)
Other versions
JP7393943B2 (ja
JP2019524821A (ja
Filing date
Publication date
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Priority claimed from PCT/IB2017/054928 external-priority patent/WO2018029657A1/en
Application filed filed Critical
Publication of JP2019524821A publication Critical patent/JP2019524821A/ja
Publication of JP2019524821A5 publication Critical patent/JP2019524821A5/ja
Priority to JP2022001694A priority Critical patent/JP2022050564A/ja
Publication of JP7393943B2 publication Critical patent/JP7393943B2/ja
Application granted granted Critical
Priority to JP2024027864A priority patent/JP7757446B2/ja
Priority to JP2025170034A priority patent/JP2025188157A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019507811A 2016-08-11 2017-08-11 リソソーム蓄積障害に関する医薬組成物及び使用 Active JP7393943B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022001694A JP2022050564A (ja) 2016-08-11 2022-01-07 リソソーム蓄積障害に関する医薬組成物及び使用
JP2024027864A JP7757446B2 (ja) 2016-08-11 2024-02-27 リソソーム蓄積障害に関する医薬組成物及び使用
JP2025170034A JP2025188157A (ja) 2016-08-11 2025-10-08 リソソーム蓄積障害に関する医薬組成物及び使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1613828.1 2016-08-11
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GB1702552.9 2017-02-16
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GB1705762.1 2017-04-10
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GB1706854.5 2017-04-28
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
PCT/IB2017/054928 WO2018029657A1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022001694A Division JP2022050564A (ja) 2016-08-11 2022-01-07 リソソーム蓄積障害に関する医薬組成物及び使用

Publications (3)

Publication Number Publication Date
JP2019524821A JP2019524821A (ja) 2019-09-05
JP2019524821A5 true JP2019524821A5 (https=) 2020-09-17
JP7393943B2 JP7393943B2 (ja) 2023-12-07

Family

ID=59859423

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019507811A Active JP7393943B2 (ja) 2016-08-11 2017-08-11 リソソーム蓄積障害に関する医薬組成物及び使用
JP2022001694A Pending JP2022050564A (ja) 2016-08-11 2022-01-07 リソソーム蓄積障害に関する医薬組成物及び使用
JP2024027864A Active JP7757446B2 (ja) 2016-08-11 2024-02-27 リソソーム蓄積障害に関する医薬組成物及び使用
JP2025170034A Pending JP2025188157A (ja) 2016-08-11 2025-10-08 リソソーム蓄積障害に関する医薬組成物及び使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022001694A Pending JP2022050564A (ja) 2016-08-11 2022-01-07 リソソーム蓄積障害に関する医薬組成物及び使用
JP2024027864A Active JP7757446B2 (ja) 2016-08-11 2024-02-27 リソソーム蓄積障害に関する医薬組成物及び使用
JP2025170034A Pending JP2025188157A (ja) 2016-08-11 2025-10-08 リソソーム蓄積障害に関する医薬組成物及び使用

Country Status (30)

Country Link
US (4) US11400067B2 (https=)
EP (4) EP3482754B1 (https=)
JP (4) JP7393943B2 (https=)
KR (4) KR20220154849A (https=)
CN (3) CN109843275B (https=)
AU (3) AU2017308864B2 (https=)
CA (1) CA3033557A1 (https=)
CY (2) CY1121345T1 (https=)
DK (2) DK3359146T3 (https=)
ES (2) ES2849566T3 (https=)
FI (1) FIC20260014I1 (https=)
HK (1) HK1253282B (https=)
HR (2) HRP20190344T1 (https=)
HU (2) HUE052837T2 (https=)
IL (2) IL314107A (https=)
LT (2) LT3482754T (https=)
MA (2) MA43876B1 (https=)
MD (2) MD3359146T2 (https=)
ME (1) ME03340B (https=)
MX (2) MX384447B (https=)
NZ (3) NZ790895A (https=)
PL (2) PL3482754T3 (https=)
PT (2) PT3482754T (https=)
RS (2) RS61442B1 (https=)
RU (1) RU2749515C2 (https=)
SG (1) SG11201901048VA (https=)
SI (2) SI3359146T1 (https=)
SM (2) SMT202100050T1 (https=)
TN (1) TN2019000032A1 (https=)
WO (1) WO2018029657A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3359146T3 (en) * 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
EP3886986A1 (en) * 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
SMT202400334T1 (it) * 2019-03-02 2024-09-16 Intrabio Ltd (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
RS67283B1 (sr) 2019-06-28 2025-11-28 Intrabio Ltd Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2883180B1 (fr) 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (en) * 2008-03-14 2009-09-17 Irm Llc Compounds, compositions and methods for treating lysosomal storage diseases and disorders
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
GB201114017D0 (en) 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
JP2015518872A (ja) 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用
KR102247701B1 (ko) 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES

Similar Documents

Publication Publication Date Title
JP2019524821A5 (https=)
RU2019106493A (ru) Фармацевтические композиции и применения против лизосомных болезней накопления
US20180360807A1 (en) Methods for the treatment of diseases ameliorated by pde4 inhibition using dosage titration of apremilast
US9872854B2 (en) Methods for the treatment of psoriatic arthritis using apremilast
JP2011525500A5 (https=)
Bhat et al. Moisture-tolerant resin-based sealant: a boon
EP4563150A3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
WO2004028521A3 (en) Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
MX395710B (es) Composiciones gomosas de multicomponentes con nucleo duro.
WO2008112525A3 (en) Treatment of lysosomal storage diseases
TNSN08140A1 (https=)
RU2017105470A (ru) Способы лечения парамиксовирусов
WO2020086747A3 (en) Ssao inhibitors and uses thereof
NO20082498L (no) Diarylurea for behandling av pulmonar hypertensjon
MX2022005679A (es) Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden.
HK1244429A1 (zh) 特别用於治疗注意力缺陷障碍的方法和组合物
WO2008148755A3 (en) Novel 5-substituted hydantoins
JP2018537507A5 (https=)
WO2016126085A3 (ko) 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물
TW200745047A (en) Heterocyclic compounds
JP2021526021A5 (https=)
Takeshita et al. Randomized Crossover Comparison of the Short‐Term Efficacy and Safety of Single Half‐Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
JP2014532758A5 (https=)
HRP20210047T1 (hr) Arimoclomol za liječenje poremećaja povezanih s glukocerebrozidazom
CN114364676A (zh) 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用